From Public Record to Resolution
AppliedXL identifies commitments in public records, tracks the events attached to them, and establishes outcomes with evidence you can review. The resulting record supports prediction-market resolution and analysis of financial commitments.
Extract the terms that matter.
AppliedXL identifies who committed to what, the relevant event or condition, timing and qualifications. Each record retains the original source language and distinguishes an announced plan from a contractual obligation.
In October 2025 the second milestone related to the fourth patient dosed in a Phase 3 clinical trial of felzartamab for IgAN was achieved, resulting in a $150.0 million milestone payment made to the former shareholders of HI-Bio, which was paid during the fourth quarter of 2025.
- Entity
- Biogen / former HI-Bio shareholders
- Asset
- Felzartamab · IgAN · Phase 3
- Commitment
- $150 million milestone payment; contingent on the dosing milestone
- Condition
- Fourth patient dosed in the Phase 3 trial
- Timing
- Milestone achieved October 2025; paid Q4 2025
- Source
- Biogen’s 2025 Form 10-K · filed 6 February 2026
Historical example reconstructed from public disclosures. The filing retrospectively describes a contingent payment and its satisfaction; this is not evidence of advance knowledge of the terms.
Connect new evidence to the original commitment.
AppliedXL monitors subsequent disclosures and connects them to the relevant company, asset and event. Updates, amendments and delays remain linked to the original record, preserving what was known at each point.
- October 2025Event occurrenceMilestone achieved: fourth patient dosed in the Phase 3 felzartamab trial for IgAN.
- Q4 2025Payment occurrence$150 million paid to former HI-Bio shareholders.
- 6 February 2026Public disclosure · cited filingBiogen’s 2025 Form 10-K reports the milestone and confirms payment. This filing date is neither the event date nor the payment date.
- Not recorded hereDetectionNo historical detection timestamp is asserted. The reconstruction does not establish when AppliedXL first observed the disclosure.
The source supplies periods, not exact event or payment days. This chronology does not claim that the cited filing was the first public disclosure.
Evaluate the evidence against the recorded criteria.
AppliedXL assesses whether the evidence satisfies the relevant conditions and records what is met, not met or unresolved. Each determination includes its supporting sources, reasoning and any documented financial consequence.
| Criterion | Evidence | Finding |
|---|---|---|
| Recorded condition is satisfied | A controlling source supports the required event or result, with the applicable qualifications. | MetState which condition the evidence satisfies. |
| Recorded condition is not satisfied | The evidence shows a required result failed, or a required deadline was missed. | Not metKeep separate reasons separate. |
| Evidence is insufficient or conflicting | The available sources do not establish whether the condition is satisfied. | UnresolvedA missing record is not proof of failure. |
Findings remain linked to the criteria and the source passages. The applicable terms determine their consequences; satisfied conditions do not offset a failed mandatory condition.
Resolve market questions against published rules.
AppliedXL evaluates evidence against a market’s published criteria and prepares a documented resolution recommendation. The exchange independently determines the outcome.
Illustrative example: all names, figures, dates and disclosures in this clinical-trial example are illustrative, not an actual market or settlement.
The process is limited to public information. AppliedXL does not use identifiable patient data, confidential clinical records, material nonpublic information, or undisclosed information from sponsors or other third parties.
Assess candidates before listing.
Candidate review considers objective outcomes, endpoints, timing, controlling public sources and potential effects on patients, recruitment, investigators or clinical conduct. AppliedXL may recommend candidates. The exchange decides what to list and sets the final contract terms.
Candidate assessment and resolution requirements
Illustrative quoted price: 41¢. This example figure is not live market data and does not determine the contract’s resolution.
Contract terms and resolution basis
- Controlling sources
- The public sources and source hierarchy identified in the official contract terms.
- Required result
- Both specified primary endpoints must meet the criteria: overall survival HR < 1.00, p < 0.05; objective response rate at or above the protocol target.
- Public-reporting deadline
- The qualifying result must be publicly reported on or before 30 Jun 2026 through the contract’s controlling sources.
- Illustrative YES treatment
- Both required endpoints meet their criteria and the qualifying public disclosure is timely.
- Illustrative NO treatment
- A disclosed failure of either required endpoint is sufficient for NO. Failure to publish a qualifying result by the deadline is also sufficient for NO under this example’s terms.
- Review period
- Review may continue after the deadline to verify evidence and timing. It does not extend the public-reporting deadline or make a late disclosure timely.
- Other records
- The official contract must specify treatment of amendments, delays, corrections and conflicting records. Unresolved evidence requires further review under those terms and the exchange’s rules.
These are illustrative terms, not rules for all markets. The official exchange contract terms and rules govern in every case.
…median overall survival did not reach statistical significance (HR 0.91, p = 0.14) versus the control arm…
Company characterization is not the resolution criterion. The endpoint data and publication timing are checked against the recorded terms. The event’s exact occurrence date is not established by this illustrative disclosure.
| Criterion | Evidence | Finding |
|---|---|---|
| Primary endpoint 1 · Overall SurvivalHR < 1.00, p < 0.05 | “…median overall survival did not reach statistical significance (HR 0.91, p = 0.14) versus the control arm…” | Not metRequired endpoint failed the specified significance criterion. |
| Primary endpoint 2 · Objective Response RateORR ≥ protocol target | “…objective response rate improved by 19 points (p < 0.01), clearing the prespecified threshold…” | MetDoes not offset failure of another mandatory condition. |
| Public-reporting deadlineOn or before 30 Jun 2026 | Published Aug 1, 2026. Detected Aug 1, 2026. Publication occurred after the deadline. | Not metLate publication is distinct from endpoint failure; detection does not establish timeliness. |
Conditional recommendation: NO under the illustrative contract treatment stated above. The overall-survival endpoint fails a mandatory criterion. Separately, publication on Aug 1, 2026 misses the 30 Jun 2026 deadline. Either finding supports NO under these stated terms; other contracts may treat them differently.
Before submission, a qualified specialist reviews the terms, sources, extracted evidence, publication and detection dates, amendments and conflicting records. No actual reviewer identity or completed sign-off is asserted in this example.
AppliedXL reviewers are prohibited from trading in prediction markets and may not hold a financial interest in the outcome.
The exchange may accept the recommendation, request additional evidence or reach a different conclusion. It remains the sole and final adjudicator. AppliedXL’s recommendation does not settle the contract; no contract pays out until the exchange finalizes the outcome.
Track the events that change financial commitments.
AppliedXL identifies the conditions behind milestone payments, funding options and other contingent commitments. It follows the evidence to establish what remains conditional, what has become obligatory and what has been paid.
Biogen / HI-Bio · felzartamab IgAN milestone
Historical example reconstructed from public disclosures.
Condition
The fourth patient is dosed in the Phase 3 felzartamab trial for IgAN.
The payment is contingent on this dosing milestone.Event
Biogen reports that the milestone was achieved in October 2025.
Condition satisfaction is established retrospectively by the cited filing. No exact event day is supplied.Financial consequence
Achievement triggers a $150 million payment obligation to former HI-Bio shareholders.
The payment obligation is distinct from both the dosing event and confirmation that cash was paid.Settlement
Biogen’s annual filing confirms that payment occurred during Q4 2025.
Confirmed payment, not merely an obligation. No exact payment day is supplied.Supporting filing and date qualifications
Biogen’s 2025 Form 10-K, filed 6 February 2026, states:
In October 2025 the second milestone related to the fourth patient dosed in a Phase 3 clinical trial of felzartamab for IgAN was achieved, resulting in a $150.0 million milestone payment made to the former shareholders of HI-Bio, which was paid during the fourth quarter of 2025.
October 2025 is the reported milestone period; Q4 2025 is the reported payment period. The filing date is a separate public-record date. No detection timestamp, live monitoring claim or advance knowledge of the terms is asserted.
The record supports assessment of cash exposure and liquidity. Credit significance depends on the issuer’s financial position, timing and other obligations.
The payment alone does not establish a rating change or credit deterioration.
Every determination has a reviewable basis.
The record connects the original terms, supporting passages, relevant dates, amendments, reasoning and review history.
- Terms and conditions
- Clinical-trial contract criteria are illustrative. The Biogen milestone condition is reconstructed from the cited annual filing, not a claim that the original acquisition agreement was reviewed.
- Supporting evidence
- Trial: illustrative company disclosure and endpoint results. Cash & credit: the linked Biogen filing and its quoted milestone-payment passage.
- Relevant dates
- Trial: deadline 30 Jun 2026; published Aug 1, 2026; detected Aug 1, 2026. Biogen: event October 2025; payment Q4 2025; filing 6 February 2026; no detection timestamp asserted.
- Reasoning
- Trial: endpoint failure and late publication separately support conditional NO under the stated illustrative treatment. Biogen: milestone achieved, payment obligation triggered, payment confirmed.
- Review history
- Required specialist review and exchange handoff are described, not simulated. No reviewer identity, completed sign-off or actual exchange settlement is presented.
Essential uncertainty: exact Biogen event and payment days are not supplied. This historical reconstruction does not establish advance knowledge or detection timing. The clinical-trial recommendation is illustrative and contract-dependent.
Supplementary provenance and amendments
Biogen’s 2025 Form 10-K, filed 6 February 2026 is the cited source for the historical milestone, financial consequence and payment. Its reported periods are retained without adding day-level precision.
No amendment history or actual specialist sign-off is supplied for these examples. In an operational record, documented amendments and reviews remain linked to the relevant evidence; missing history is not represented as confirmation that no amendments occurred.